

Prostaglandins

Vitamin D derivatives(19) Pneumocandins(4) APIs & Intermediates [Custom Synthesis](#)

Prostaglandins

Latanoprost [HOT]

Travoprost


Bimatoprost

Dinoprostone (Prostaglandin E2)

Alprostadil (Prostaglandin E1)

Latanoprost, 130209-82-4, >99%

Latanoprost



CAS

Molecular

Formula

Molecular
Weight

System
Name

Assay

View via
file

Specification

Appearance	Colorless or pale yellow oil	Compliance
Identification		
(1) by HPLC	the retention time of the major peak corresponds to the standard preparation.	Compliance
(2) by IR	Both the test sample and the reference standard exhibit the same intensity of the absorption at the same wave.	Compliance
Optical rotation	+32.0° to +38.0°	35°
Water	Not more than 0.5%	0.2%
Residual substance	15(s)-cis isomer: N.M.T:0.1%	Not detected
	15(s)-trans isomer: N.M.T:0.1%	Not detected
	15(r)-trans isomer: N.M.T:0.1%	Not detected
	Any single impurity: N.M.T:0.1%	0.06%
	Total impurities: N.M.T:1.0%	0.11%
Residual solvents	n-Hexane: N.M.T:0.05%	Not detected
	Ethanol: 1.0%	0.11%
Assay	96.0% to 102.0%	99.3%

Related Prostaglandins

Latanoprost [HOT]

Travoprost

Bimatoprost

Dinoprostone (Prostaglandin E2)

Alprostadil

Patent Disclaimer

PD1	Products protected by valid patents are not covered by such products constitutes a patent infringement. Products and technologies that are available, may be developed or produced for internal use.
PD2	Sales of products are limited to those allowed by law. This includes Research and development quantities.
PD3	The buyer assumes responsibility of all patents. Latanoprost's Pharmaceutical Co., Ltd product(s).

PD4

R&D use in accordance with (1) 35 USC 271 Japanese Patent Law in Japan; (3) Section 1 Germany; (iv) Section 60, Paragraph 5b of th Sections 55.2(1) and 55.2(6) and other comr (5) Section 68B of the Patents Act of 1953 in of same by the Statutes Amendment Bill of 2 law as may be or become applicable in the a laws and rules as may apply in various other

Friend link: www.meilipharma.com